Compare Danaher Corporation (DHR) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs JPMorgan Chase & Co — how do they compare? Danaher Corporation trades at $219.24 (market cap $152.87B), while JPMorgan Chase & Co trades at $331.31 (market cap $880.98B). The key difference: JPMorgan Chase & Co is far larger — about 5.8× Danaher Corporation's market cap, and JPMorgan Chase & Co pays the higher dividend (1.99%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and JPMorgan Chase & Co for 127 Days on average.
| DHR | JPM | |
|---|---|---|
Market Cap | $152.87B | $880.98B |
Volume | 5,228,698 | 7,721,661 |
Sector | Health | Financials |
52-Week High | $242.05 | $365.18 |
52-Week Low | $161.91 | $282.84 |
Typical Hold Time | 69 Days | 127 Days |
Enterprise Value | $175.08B | $1.82T |
Dividend Yield | 0.74% | 1.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
JPMorgan Chase (JPM) trades at $329.58, down 0.51% with a bearish technical signal. The stock shows strong fundamentals with revenue growth from $181.85B in 2025 to $194.9B projected for 2026, and a net income margin of 33.38%. Recent earnings beat expectations in Q1 and Q2 2026, while analyst consensus remains positive with a $373.18 price target. However, negative cash flow trends and geopolitical risks noted by CEO Jamie Dimon present headwinds.
Outlook: JPM offers solid value with a P/E of 14.2 and high ROE of 18.43%, supported by earnings beats and institutional buying. Risks include sustained negative operating cash flow, rising debt-to-asset ratio (11.34% in 2024), and macroeconomic volatility. The stock is a hold for long-term investors, with upside to consensus target if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
